Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2022-03-30
2022-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The Nictavi Tarsus Patch is a new medical device that uses a flexible material that conforms to the upper eyelid curvature while maintaining sufficient rigidity to keep the upper eyelid in a closed position. It also is designed to be placed above the eyelash line, which allows for enhanced comfort. There has been no study to date evaluating the Tarsus Patch for its effectiveness, safety, or tolerability.
The purpose of this study is to determine the effectiveness, safety, and tolerability of the Tarsus Patch in managing lagophthalmos in children and adolescents overnight. The investigators hypothesize that there will be a significant improvement in eyelid closure when using the Tarsus Patch when compared to not using any device and that over 90% of subjects will achieve complete eyelid closure with its use. The investigators also hypothesize there will be no complications related to the use of the Tarsus Patch, and that it will be considered by patients and parents to be comfortable, easy to use, and, overall, preferable to other available methods of nocturnal eyelid closure.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Suture Lid Spring for Lid Closure in Patients With Facial Nerve Palsy
NCT06895902
Telemedicine Follow-up for Routine, Low-Risk Oculoplastic Surgery
NCT04235803
Comparison Between Two Surgical Methods for Eyelid Ectropion: Tarsal Strip Alone Versus Tarsal Strip With Punctoplasty (Three Snips With or Without Diamond-shaped Resection)
NCT02893813
Hyaluronic Acid Gels for Lower Lid Retraction
NCT01838252
Lacrimal Drainage Resistance Study
NCT01766232
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PROCEDURES INVOLVED
* Study visit (Day 1 of study, 60 minute commitment):
* At the study visit, informed consent will be obtained by the study coordinator or investigator.
* Once consent is obtained, the enrolled subject then undergoes an ophthalmic history and examination, including dilated examination if deemed necessary for their usual ophthalmic care. The history will include usual questions asked at a follow-up visit about ocular health and will also include details about how often, in which eye, and with what method they close their eyelids at night.
* The examination will include standard measures of vision, ocular surface health, and eyelid position and function.
* If the subject has unilateral lagophthalmos, then the involved eye will be designated as the study eye. If the subject has bilateral lagophthalmos, then the eye with more severe lagophthalmos will be designated as the study eye.
* The parent will receive an explanation about the procedures of the study.
* The study investigator will choose which Tarsus Patch size (pediatric or adult) will fit best on the child's eyelid. With the proper size, the parent will then be shown how to properly place the Tarsus Patch on the study eye, and questions will be answered about how to properly place the patch on the eye.
* The parent will then be given the following items to take home: 6 patches (this includes a few extra patches in case they are needed), and a copy of the study consent form including email and phone number to reach the study team should they have any questions
* To minimize risk, the parent will be informed that if the subject has any discomfort with an of the study protocols, they should stop the use of the Patch call the study team to discuss how to address the issue.
* At home portion (Day 1-3 of study):
\- Each night for 3 nights, the parent should place a new Tarsus Patch on the subject's study eye and then place a ½ cm strip of ophthalmic ointment or gel into the study eye. The parent should then help remove the patch the next morning and throw it away.
* Phone survey (Day 4):
* A study investigator will call the parents to have them respond to the Parent Survey over the phone in the absence of the study subject.
* If the subject is 10 years of age or older and cognitively able to answer the survey questions, then they will be asked to answer the Subject Survey over the phone with the help of the parent.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DEVICE_FEASIBILITY
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tarsus Patch Group
All subjects will receive the Tarsus Patch to be worn and evaluated by the investigator in the clinic and to also be worn at home for 3 nights.
Tarsus Patch
The Tarsus Patch is a flexible adhesive device that is applied to the closed upper eyelid and conforms to the curvature of the eyelid to help keep the eyelid in a closed position.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tarsus Patch
The Tarsus Patch is a flexible adhesive device that is applied to the closed upper eyelid and conforms to the curvature of the eyelid to help keep the eyelid in a closed position.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Between 0 and 17 years old (inclusive)
* Diagnosis of unilateral or bilateral lagophthalmos based upon an eye examination since Jan 1, 2019
* Previously recommended to use an eyelid closure method (such as using medical tape, steristrips, moisture chambers, temporary tarsorrhaphy, etc).
* English-speaking
* Able to participate in an age-appropriate manner for the eye examination
* Parent subjects:
* 18 years or older
* English-speaking
Exclusion Criteria
* Presence of corneal abrasion or corneal ulcer on the study eye
* Active use of bandage contact lens in the study eye
* Active dermatitis affecting the eyelids
* Inability to tolerate the Tarsus Patch in clinic
* Inability for complete mechanical closure of the eyelid by any means
* Allergy to adhesive
* Parent subjects:
* Prisoners
17 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Angeline Nguyen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Angeline Nguyen
Assistant Professor of Clinical Ophthalmology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Angeline M Nguyen, MD
Role: PRINCIPAL_INVESTIGATOR
Children's Hospital Los Angeles
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Hospital Los angeles
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Latkany RL, Lock B, Speaker M. Nocturnal lagophthalmos: an overview and classification. Ocul Surf. 2006 Jan;4(1):44-53. doi: 10.1016/s1542-0124(12)70263-x.
Masoudi Alavi N, Sharifitabar Z, Shaeri M, Adib Hajbaghery M. An audit of eye dryness and corneal abrasion in ICU patients in Iran. Nurs Crit Care. 2014 Mar;19(2):73-7. doi: 10.1111/nicc.12052. Epub 2013 Oct 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHLA-21-00354
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.